Sanofi SA (SASY)

102.28
-0.44(-0.43%)
  • Volume:
    1,154
  • Bid/Ask:
    102.26/102.28
  • Day's Range:
    102.28 - 103.40
  • Type:Equity
  • Market:Germany
  • ISIN:FR0000120578
  • WKN:920657

SASY Overview

Prev. Close
102.72
Day's Range
102.28-103.4
Revenue
-
Open
102.7
52 wk Range
81.1-105.92
EPS
-
Volume
1,154
Market Cap
127.84B
Dividend (Yield)
3.33
(3.26%)
Average Vol. (3m)
1,444
P/E Ratio
18.14
Beta
-
1-Year Change
16.38%
Shares Outstanding
1,248,657,151
Next Earnings Date
Jul 28, 2022
What is your sentiment on Sanofi?
or
Market is currently closed. Voting is open during market hours.

Sanofi SA News

Sanofi SA Analysis

Sanofi SA Company Profile

Sanofi SA Company Profile

Employees
95442
Market
France

Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellNeutralNeutralBuyStrong Buy
Technical IndicatorsStrong SellStrong SellSellStrong BuyStrong Buy
SummaryStrong SellSellNeutralStrong BuyStrong Buy
  • what Is going on?
    0
    • huge results coming
      0
      • target price 110€ according to investir
        0
        • SASY is creating separate company Opella World Wide to separate CHC/OTC business. With standard business they may look for a merger. I think we could expect a merger with GSK.
          0
          • Indietro tutta con problemi legali!!!???
            0
            • Sanofi
              0
              • Vola occhio!!
                0
                • Sanofi Stuck as it’s not involved in the vaccine process; this is so disturbing
                  1
                  • Very good earnings, to the moonnnnnn
                    2
                    • sanofi will participate in the production of the pfizer vaccine !!! In addition to continuing with their own vaccine, which will be the safest of all due to the protocols they are following in the manufacture. Sanofi does not enter false advertisements and plays with the news on the stock market to enrich its managers. It is a much more reliable company than other pharmaceutical companies that are developing the vaccine.
                      0